Abstract
BackgroundEvidence suggests that patients on aromatase inhibitors (AIs) for breast cancer treatment are at an increased risk of bone loss therefore during AI treatment they continuously have their bone mineral...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
